Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years~* B-ALL in relapse~* refractory B-ALL-performance status of 0-2 on the Eastern Cooperative Oncology Group scale~* adequate hepatic and renal functions (AST or ALT \<= 5 times the upper limit of normal creatinine \< 2 times the upper limit of normal)~* \> 20% blasts in bone marrow,~* \> 30% of bone marrow blast population HER2 positive as assessed by immunophenotyping~Exclusion Criteria:~* Previous treatment by trastuzumab~* FEVG \< 50%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).